|
pubmed:abstractText |
Bone health in men with prostate cancer on androgen deprivation therapy (ADT) has gained increased attention in recent years. Therapies that are becoming available to prevent bone loss and associated complications are changing practice for this patient population. In addition to basic vitamin D and calcium supplementation, bisphosphonates may be an option to treat these patients, and denosumab, a receptor activator of nuclear factor-?B ligand inhibitor, has been proven to be effective in preventing bone loss through a randomized clinical trial. This review examines the importance of bone health in patients on ADT, with an overview of available treatment modalities and guidelines for managing these patients.
|
|
pubmed:affiliation |
Departments of Surgery and Urology, Centre Hospitalier de l'Université de Montréal, 1560 Sherbrooke East, Montreal, Quebec H2L 4M1, Canada. jean-baptiste.lattouf@umontreal.ca
|
